TG Therapeutics, Inc. (TGTX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases. Its primary commercial product is BRIUMVI (ublituximab-xiiy), approved for relapsing forms of multiple sclerosis (RMS). The company also has a pipeline including a subcutaneous formulation of BRIUMVI and azer-cel, an allogeneic CAR T therapy for autoimmune diseases.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $141.1 million | $73.5 million | $262.0 million | $136.9 million |
| Net Income (Loss) | $28.2 million | $6.9 million | $33.2 million | $(3.8) million |
| Operating Income | $34.8 million | $8.8 million | $43.5 million | $(0.5) million |
| Diluted EPS | $0.17 | $0.04 | $0.20 | $(0.03) |
| Cash & Investments | $278.9 million (as of June 30, 2025) | |||
| Total Debt | $245.0 million (Net of issuance costs) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 92% year-over-year for the quarter and 91% year-over-year for the six months ended June 30, 2025. This was driven primarily by a 91% increase in net product revenue from BRIUMVI sales in the U.S. ($138.8M vs. $72.6M in Q2 2024).
- Profitability: The company reported net income of $28.2 million for Q2 2025, compared to $6.9 million in Q2 2024. For the six-month period, the company turned a net loss of $3.8 million in 2024 into a net income of $33.2 million in 2025.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased to $31.8 million (Q2 2025) from $17.6 million (Q2 2024), driven by subcutaneous BRIUMVI development and clinical pipeline costs. Selling, General, and Administrative (SG&A) expenses rose to $55.6 million from $38.8 million due to commercialization scaling.
- Stock Repurchases: The company repurchased 193,500 shares of common stock in Q2 2025 at a cost of $6.9 million under its $100 million share repurchase program.
Guidance, Outlook, and Risks
- Liquidity: Management anticipates that cash, cash equivalents, and investment securities ($278.9 million) combined with projected revenues will provide sufficient liquidity for more than 12 months.
- Debt Obligations: The company holds a $250 million term loan facility with Blue Owl Capital (maturity August 2029). Interest expense increased to $6.7 million in Q2 2025 from $4.0 million in Q2 2024 due to this facility.
- Development Pipeline:
- Subcutaneous BRIUMVI: Phase 3 pivotal program enrollment is set to commence to evaluate dosing schedules compared to IV BRIUMVI.
- Azer-cel: First patient with progressive multiple sclerosis was dosed in a Phase 1 trial in August 2025.
- Risks: Key risks include dependence on third-party manufacturers (Samsung Biologics), regulatory approval uncertainties for new formulations, competition in the RMS market, and the impact of potential pricing regulations or reimbursement changes.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of BRIUMVI market penetration and the impact of gross-to-net adjustments (rebates, chargebacks) on net revenue.
- Debt Covenants: Review the specific financial covenants in the Blue Owl Capital term loan agreement to ensure compliance with leverage ratios and sales thresholds.
- Inventory Levels: Assess the $155.2 million inventory balance (up from $110.5 million at year-end 2024) to ensure it aligns with sales forecasts and shelf-life constraints.
- Stock-Based Compensation: Note the significant non-cash compensation expense ($16.4 million in Q2 2025) and its impact on future cash burn and dilution.
- Ex-US Commercialization: Monitor the performance of the Neuraxpharm partnership for ex-U.S. sales and the recognition of milestone payments.